Ignite Creation Date:
2025-12-25 @ 1:11 AM
Ignite Modification Date:
2025-12-27 @ 1:46 AM
Study NCT ID:
NCT04728893
Status:
RECRUITING
Last Update Posted:
2025-12-24
First Post:
2021-01-25
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D019337', 'term': 'Hematologic Neoplasms'}, {'id': 'D008258', 'term': 'Waldenstrom Macroglobulinemia'}, {'id': 'D008228', 'term': 'Lymphoma, Non-Hodgkin'}, {'id': 'D015448', 'term': 'Leukemia, B-Cell'}], 'ancestors': [{'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D006402', 'term': 'Hematologic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}, {'id': 'D054219', 'term': 'Neoplasms, Plasma Cell'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D020141', 'term': 'Hemostatic Disorders'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D010265', 'term': 'Paraproteinemias'}, {'id': 'D001796', 'term': 'Blood Protein Disorders'}, {'id': 'D006474', 'term': 'Hemorrhagic Disorders'}, {'id': 'D008232', 'term': 'Lymphoproliferative Disorders'}, {'id': 'D008206', 'term': 'Lymphatic Diseases'}, {'id': 'D007160', 'term': 'Immunoproliferative Disorders'}, {'id': 'D007154', 'term': 'Immune System Diseases'}, {'id': 'D008223', 'term': 'Lymphoma'}, {'id': 'D007945', 'term': 'Leukemia, Lymphoid'}, {'id': 'D007938', 'term': 'Leukemia'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000721068', 'term': 'ARQ531'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 490}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2021-04-05', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-12', 'completionDateStruct': {'date': '2029-01-04', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-12-23', 'studyFirstSubmitDate': '2021-01-25', 'studyFirstSubmitQcDate': '2021-01-25', 'lastUpdatePostDateStruct': {'date': '2025-12-24', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2021-01-28', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2029-01-04', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Part 1: Number of participants experiencing dose-limiting toxicities (DLTs)', 'timeFrame': 'Up to ~56 days (Cycles 1-2, cycle = 28 days)', 'description': 'DLTs will be defined as toxicities observed during the first 2 cycles (8 weeks) of Part 1 and include: Grade ≥3 nonhematologic toxicity (except Grade 3 nausea, vomiting, diarrhea, rash, fatigue, and uncontrolled hypertension which will not be considered a DLT unless lasting ≥72 hours despite optimal supportive care); Grade 4 hematologic toxicity lasting \\>7 days (except Grade 3 lymphocytosis, Grade 4 platelet count decreased of any duration, or Grade 3 platelet count decreased if associated with bleeding); any Grade 3 or Grade 4 nonhematologic laboratory abnormality if values result in drug-induced liver injury, or medical intervention is required, or the abnormality leads to hospitalization, or the abnormality persists for \\>1 week (with exceptions); missing \\>25% of nemtabrutinib doses as a result of drug-related adverse events (AEs) during the first 2 cycles (8 weeks); Grade 5 toxicity.'}, {'measure': 'Part 1: Number of participants experiencing adverse events (AEs)', 'timeFrame': 'Up to ~71 months', 'description': 'An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants experiencing AEs will be reported for Part 1.'}, {'measure': 'Part 1: Number of participants discontinuing study treatment due to AEs', 'timeFrame': 'Up to ~42 months', 'description': 'An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants discontinuing study treatment due to an AE will be reported for Part 1.'}, {'measure': 'Part 2: Objective Response Rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria 2018 as assessed by independent central review (ICR)', 'timeFrame': 'Up to ~61 months', 'description': 'ORR per iwCLL 2018 criteria is defined as the percentage of participants achieving a complete response (CR), complete response with incomplete bone marrow recovery (CRi), nodular partial response (nPR), or partial response (PR). CR is defined as meeting the following criteria: no lymph nodes \\>1.5 cm, spleen size \\<13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10\\^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10\\^9/L or ≥50% increase from screening, hemoglobin \\>11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow.'}, {'measure': 'Part 2: ORR per Lugano criteria 2014 as assessed by ICR', 'timeFrame': 'Up to ~61 months', 'description': 'ORR per Lugano criteria 2014 is defined as the percentage of participants achieving a CR or PR. CR defined as EITHER CR by imaging (computed tomography \\[CT\\]): all lymph nodes normal (none ≥15 mm) and normal liver and spleen OR complete metabolic response (CMR): score of 1, 2 or 3 on the 5-point scale assessing fluorodeoxyglucose (FDG) metabolic activity in lymphomatous lesions (ranging from 1=no uptake above background to 5=uptake markedly higher than liver) AND bone marrow (BM) normal by morphology. PR defined as EITHER PR by imaging (CT) with ≥50% decrease in the sum of the product of diameters \\[SPD\\] of target lesions, no worsening of nontarget lesions, no new lesions and ≥50% spleen abnormal portion OR Partial Metabolic Response (PMR) with score of 4 or 5 on the FDG 5-point scale (with no new lesions) and decreased overall uptake AND residual BM abnormalities; OR CR by imaging with residual BM abnormalities; OR PR by imaging without residual BM abnormalities.'}, {'measure': "Part 2: ORR per International Workshop on Waldenström's Macroglobulinemia (IWWM) criteria 2014 as assessed by ICR", 'timeFrame': 'Up to ~71 months', 'description': 'ORR per IWWM criteria 2014 is defined as the percentage of participants achieving a CR, very good partial response (VGPR), or PR. CR is defined as all lymph nodes are normal in size (none ≥15 mm), liver and spleen normal in size, serum immunoglobulin M (IgM) values in the normal range, disappearance of monoclonal protein by immunofixation (confirmation needed with a second immunofixation at any subsequent timepoint), and no histological evidence of BM involvement. VGPR is defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in the abnormal portion of the spleen (if previously abnormal), and ≥90% decrease from baseline in serum IgM, or serum IgM values in normal range. PR is defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in serum IgM, and ≥50% decrease from baseline in the abnormal portion of the spleen (if previously abnormal).'}], 'secondaryOutcomes': [{'measure': 'Part 1: Area Under the Curve (AUC) of Nemtabrutinib', 'timeFrame': 'At designated time points (up to ~57 days)', 'description': 'Blood samples will be obtained at designated time points during Part 1 for the assessment of nemtabrutinib AUC (Day 1 of Cycles 1 and 2: Pre-dose, 2, 4, 6, 8, and 24 hours post-dose; Day 1 of Cycle 3: pre-dose and 2, 4, and 6 hours post-dose \\[up to \\~57 days\\]). Each cycle is 28 days.'}, {'measure': 'Part 1: Minimum Concentration (Cmin) of Nemtabrutinib', 'timeFrame': 'At designated time points (up to ~57 days)', 'description': 'Blood samples will be obtained at designated time points during Part 1 for the assessment of nemtabrutinib Cmin (Day 1 of Cycles 1 and 2: Pre-dose, 2, 4, 6, 8, and 24 hours post-dose; Day 1 of Cycle 3: pre-dose and 2, 4, and 6 hours post-dose \\[up to \\~57 days\\]). Each cycle is 28 days.'}, {'measure': 'Part 1: Maximum Concentration (Cmax) of Nemtabrutinib', 'timeFrame': 'At designated time points (up to ~57 days)', 'description': 'Blood samples will be obtained at designated time points during Part 1 for the assessment of nemtabrutinib Cmax (Day 1 of Cycles 1 and 2: Pre-dose, 2, 4, 6, 8, and 24 hours post-dose; Day 1 of Cycle 3: pre-dose and 2, 4, and 6 hours post-dose \\[up to \\~57 days\\]). Each cycle is 28 days.'}, {'measure': 'Part 1: ORR per iwCLL criteria 2018 as assessed by ICR', 'timeFrame': 'Up to ~71 months', 'description': 'ORR per iwCLL 2018 criteria is defined as the percentage of participants achieving a CR, CRi, nPR, or PR. CR is defined as meeting the following criteria: no lymph nodes \\>1.5 cm, spleen size \\<13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10\\^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10\\^9/L or ≥50% increase from screening, hemoglobin \\>11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow.'}, {'measure': 'Part 1: Duration of Response (DOR) per iwCLL criteria 2018 as assessed by ICR', 'timeFrame': 'Up to ~71 months', 'description': 'For participants with CR, CRi, nPR, or PR per iwCLL 2018 criteria, DOR is defined as the time from the first documented evidence of objective response until PD or death due to any cause, whichever occurs first. CR is defined as meeting the following criteria: no lymph nodes \\>1.5 cm, spleen size \\<13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10\\^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10\\^9/L or ≥50% increase from screening, hemoglobin \\>11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow.'}, {'measure': 'Part 2: Number of participants experiencing AEs', 'timeFrame': 'Up to ~61 months', 'description': 'An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants experiencing AEs will be reported for Part 2.'}, {'measure': 'Part 2: Number of participants discontinuing study treatment due to AEs', 'timeFrame': 'Up to ~42 months', 'description': 'An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants discontinuing study treatment due to an AE will be reported for Part 2.'}, {'measure': 'Part 2: AUC of Nemtabrutinib', 'timeFrame': 'At designated time points (up to ~57 days)', 'description': 'Blood samples will be obtained at designated time points during Part 2 for the assessment of nemtabrutinib AUC (Day 1 of Cycles 1, 2, and 3: Pre-dose, 2, 4, 6, hours post-dose \\[up to \\~57 days\\]). Each cycle is 28 days.'}, {'measure': 'Part 2: Cmin of Nemtabrutinib', 'timeFrame': 'At designated time points (up to ~57 days)', 'description': 'Blood samples will be obtained at designated time points during Part 2 for the assessment of nemtabrutinib Cmin (Day 1 of Cycles 1, 2, and 3: Pre-dose, 2, 4, 6, hours post-dose \\[up to \\~57 days\\]). Each cycle is 28 days.'}, {'measure': 'Part 2: Cmax of Nemtabrutinib', 'timeFrame': 'At designated time points (up to ~57 days)', 'description': 'Blood samples will be obtained at designated time points during Part 2 for the assessment of nemtabrutinib Cmax (Day 1 of Cycles 1, 2, and 3: Pre-dose, 2, 4, 6, hours post-dose \\[up to \\~57 days\\]). Each cycle is 28 days.'}, {'measure': 'Part 2: DOR per iwCLL criteria 2018 as assessed by ICR', 'timeFrame': 'Up to ~61 months', 'description': 'For participants with CR, CRi, nPR, or PR per iwCLL 2018 criteria, DOR is defined as the time from the first documented evidence of objective response until disease progression or death due to any cause, whichever occurs first. CR is defined as meeting the following criteria: no lymph nodes \\>1.5 cm, spleen size \\<13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10\\^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10\\^9/L or ≥50% increase from screening, hemoglobin \\>11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow.'}, {'measure': 'Part 2: DOR per Lugano criteria 2014 as assessed by ICR', 'timeFrame': 'Up to ~61 months', 'description': 'For participants with CR or PR per Lugano criteria 2014, DOR is defined as the time from the first documented evidence of objective response until PD or death due to any cause, whichever occurs first. CR defined as EITHER CR by imaging (CT): all lymph nodes normal (none ≥15 mm) and normal liver and spleen OR CMR: score of 1, 2 or 3 on the 5-point scale assessing FDG metabolic activity in lymphomatous lesions (ranging from 1=no uptake above background to 5=uptake markedly higher than liver and/or new lesions) AND BM normal by morphology. PR defined as EITHER PR by imaging (CT) with ≥50% decrease in the SPD of target lesions, no worsening of nontarget lesions, no new lesions and ≥50% spleen abnormal portion OR PMR with score of 4 or 5 on the FDG 5-point scale (with no new lesions) and decreased overall uptake AND residual BM abnormalities; OR CR by imaging with residual BM abnormalities; OR PR by imaging without residual BM abnormalities.'}, {'measure': 'Part 2: DOR per IWWM criteria 2014 as assessed by ICR', 'timeFrame': 'Up to ~61 months', 'description': 'For participants with CR, VGPR, or PR per IWWM criteria 2014, DOR defined as the time from first documented evidence of objective response until PD or death due to any cause, whichever occurs first. CR defined as all lymph nodes normal in size (none ≥15 mm), liver and spleen normal in size, serum IgM values in normal range, disappearance of monoclonal protein by immunofixation (confirmation needed with second immunofixation at any subsequent timepoint), and no histological evidence of BM involvement. VGPR defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in abnormal portion of the spleen (if previously abnormal), and ≥90% decrease from baseline in serum IgM, or serum IgM values in normal range. PR is defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in serum IgM, and ≥50% decrease from baseline in abnormal portion of the spleen (if previously abnormal).'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Hematologic Malignancies', 'Waldenstroms Macroglobulinaemia', 'Non-Hodgkins Lymphoma', 'Chronic Lymphocytic Leukaemia']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'https://www.merckclinicaltrials.com/', 'label': 'Merck Clinical Trials Information'}, {'url': 'https://msd.trialsummaries.com/Study/StudyDetails?id=26308&tenant=MT_MSD_9011', 'label': 'Plain Language Summary'}]}, 'descriptionModule': {'briefSummary': "The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM).", 'detailedDescription': 'This study will be performed in 2 parts: Dose Escalation and Confirmation (Part 1) and Cohort Expansion (Part 2). Following determination of the recommended phase 2 dose (RP2D) in Part 1, the study plans to proceed with Part 2 using 8 disease-specific expansion cohorts (Cohorts A to H).'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days before C1D1 (the first dose of study treatment)\n* Has a life expectancy of at least 3 months, based on the investigator assessment\n* Has the ability to swallow and retain oral medication\n* Participants who are Hepatitis B surface antigen (HBsAg)-positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization\n* Participants with history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening\n* Has adequate organ function\n* Male participants agree to refrain from donating sperm and agree to either remain abstinent from penile-vaginal intercourse as their preferred and usual lifestyle OR agree to use contraception, during the intervention period and for at least the time required to eliminate the study intervention after last dose of study intervention\n* Female participants assigned female sex at birth who are not pregnant or breastfeeding are eligible to participate if not a participant of childbearing potential (POCBP), or if a POCBP they either use a contraceptive method that is highly effective OR remain abstinent from penile-vaginal intercourse as their preferred and usual lifestyle during the intervention period and for at least to eliminate study intervention after the last dose of study intervention\n* Participants with Human immunodeficiency virus (HIV) are eligible if they meet all of the following: the CD4 count is \\>350 cells/uL at screening, the HIV viral load is below the detectable level, are on a stable ART regimen for at least 4 weeks prior to study entry, and are compliant with their ART\n\nPart 1 and Part 2 (Cohorts A to C and J)\n\n* Has a confirmed diagnosis of Chronic lymphocytic leukemia/ Small lymphocytic lymphoma (CLL/SLL) with\n\n * At least 2 lines of prior therapy (Part 1 only)\n * Part 2 Cohort A: CLL/SLL participants who are relapsed or refractory to prior therapy with a covalent, irreversible Bruton's tyrosine kinase inhibitor (BTKi), and a B-cell lymphoma 2 inhibitor (BCL2i). CLL participants must have received and failed, been intolerant to, or determined by their treating physician to be a poor phosphoinositide 3-kinase inhibitor (PI3Ki) candidate or ineligible for a PI3Ki per local guidelines\n * Part 2 Cohort B: CLL/SLL participants who are relapsed or refractory following at least 1 line of prior therapy and are BTKi treatment naive\n * Part 2 Cohort C: CLL/SLL participants with 17p deletion or tumor protein p53 (TP53) mutation who are relapsed or refractory following at least 1 line of prior therapy\n * Part 2 Cohort J: CLL/SLL participants whose disease relapsed or was refractory to prior therapy with a covalent/irreversible BTKi and BCL2i. NOTE: As of Protocol Amendment 09, at least 10 CLL/SLL participants whose disease relapsed or was refractory to prior therapy with a covalent/irreversible BTKi, BCL2i and noncovalent/reversible BTKi (all three classes of therapies are required) will be enrolled into Cohort J\n * Has active disease for CLL/SLL clearly documented to initiate therapy\n * For SLL participants in Part 2: Has evaluable core or excisional lymph node biopsy for biomarker analysis from an archival or newly obtained biopsy or bone marrow aspirate at Screening (optional for participants enrolling in Part 1)\n\nPart 2 (Cohorts D to G)\n\n\\- Has a confirmed diagnosis of and meets the following prior therapy requirements:\n\n* Participants with Richter's transformation who are relapsed or refractory following at least 1 line of prior therapy (Cohort D)\n* Participants with pathologically confirmed Mantle-cell lymphoma (MCL), documented by either overexpression of cyclin D1 or t (11;14), who are relapsed or are refractory to chemoimmunotherapy and a covalent irreversible BTKi (Cohort E)\n* Participants with Marginal zone lymphoma (MZL) (including splenic, nodal, and extra nodal MZL) who are relapsed or refractory to at least one prior line of systemic therapy including an anti-CD20-based regimen\n* Participants with Follicular lymphoma (FL) who are relapsed or refractory to chemoimmunotherapy and immunomodulatory agents (such as lenalidomide based regimen) (Cohort G)\n* Have measurable disease defined as at least 1 lesion that can be accurately measured in at least 2 dimensions with spiral Computed tomography (CT) scan\n* Has a lymph node biopsy for biomarker analysis from an archival or newly obtained biopsy or bone marrow aspirate (Cohort D) at Screening\n\nPart 2 (Cohort H): confirmed diagnosis of Waldenström's macroglobulinemia (WM); participants who are relapsed or refractory to standard therapies for WM including chemoimmunotherapy and a covalent irreversible BTKi\n\n* Has active disease defined as 1 of the following: systemic symptoms, physical findings, laboratory abnormalities, coexisting disease\n* Has measurable disease, satisfying any of the following: at least 1 lesion that can be accurately measured in at least 2 dimensions with spiral CT scan (minimum measurement must be \\>15 mm in the longest diameter or \\>10 mm in the short axis); IgM ≥450 mg/dL; or bone marrow infiltration of 10%\n* Has fresh bone marrow aspirate or a lymph node biopsy for biomarker analysis at Screening or a lymph node biopsy from an archival\n\nExclusion Criteria:\n\n* Has active HBV/HCV infection (Part 1 and Part 2)\n* Has a history of malignancy ≤3 years before providing documented informed consent. Participants with basal cell carcinoma of skin, squamous cell carcinoma of skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potential curative therapy are not excluded. Participants with low-risk, early-stage prostate cancer (T1-T2a, Gleason score ≤6, and prostate-specific antigen \\<10 ng/mL) either treated with definitive intent or untreated in active surveillance with SD are not excluded\n* Has active central nervous system (CNS) disease\n* Has an active infection requiring systemic therapy\n* Has received prior systemic anti-cancer therapy within 5 half-lives or 4 weeks (if prior therapy was a monoclonal antibody) before C1D1\n* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention\n* Has any clinically significant gastrointestinal abnormalities that might alter absorption\n* History of severe bleeding disorders"}, 'identificationModule': {'nctId': 'NCT04728893', 'briefTitle': 'Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)', 'organization': {'class': 'INDUSTRY', 'fullName': 'Merck Sharp & Dohme LLC'}, 'officialTitle': 'A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies', 'orgStudyIdInfo': {'id': '1026-003'}, 'secondaryIdInfos': [{'id': 'MK-1026-003', 'type': 'OTHER', 'domain': 'MSD'}, {'id': '2023-504931-42-00', 'type': 'REGISTRY', 'domain': 'EU CT'}, {'id': 'U1111-1290-4004', 'type': 'REGISTRY', 'domain': 'UTN'}, {'id': '2020-002324-36', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Nemtabrutinib', 'description': 'Participants receive nemtabrutinib orally once daily (QD) until progressive disease (PD) or discontinuation.', 'interventionNames': ['Drug: Nemtabrutinib']}], 'interventions': [{'name': 'Nemtabrutinib', 'type': 'DRUG', 'otherNames': ['ARQ 531', 'MK-1026'], 'description': 'Nemtabrutinib tablets administered orally QD.', 'armGroupLabels': ['Nemtabrutinib']}]}, 'contactsLocationsModule': {'locations': [{'zip': '72762', 'city': 'Springdale', 'state': 'Arkansas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '479-872-8130'}], 'facility': 'Highlands Oncology Group ( Site 2728)', 'geoPoint': {'lat': 36.18674, 'lon': -94.12881}}, {'zip': '92093-0698', 'city': 'La Jolla', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '858-534-5201'}], 'facility': 'University of California San Diego Moores Cancer Center ( Site 2717)', 'geoPoint': {'lat': 32.84727, 'lon': -117.2742}}, {'zip': '90502', 'city': 'Torrance', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '424-201-3000'}], 'facility': 'Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site 2724)', 'geoPoint': {'lat': 33.83585, 'lon': -118.34063}}, {'zip': '80218', 'city': 'Denver', 'state': 'Colorado', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '720-754-4800'}], 'facility': 'Colorado Blood Cancer Institute ( Site 2726)', 'geoPoint': {'lat': 39.73915, 'lon': -104.9847}}, {'zip': '40202', 'city': 'Louisville', 'state': 'Kentucky', 'status': 'COMPLETED', 'country': 'United States', 'facility': 'The University of Louisville, James Graham Brown Cancer Center ( Site 2729)', 'geoPoint': {'lat': 38.25424, 'lon': -85.75941}}, {'zip': '55905', 'city': 'Rochester', 'state': 'Minnesota', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '507-284-2511'}], 'facility': 'Mayo Clinic - Rochester ( Site 2706)', 'geoPoint': {'lat': 44.02163, 'lon': -92.4699}}, {'zip': '08816', 'city': 'East Brunswick', 'state': 'New Jersey', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '732-672-6405'}], 'facility': 'Astera Cancer Care ( Site 2732)', 'geoPoint': {'lat': 40.42788, 'lon': -74.41598}}, {'zip': '07601', 'city': 'Hackensack', 'state': 'New Jersey', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '551-996-3003'}], 'facility': 'John Theurer Cancer Center at Hackensack University Medical Center ( Site 2704)', 'geoPoint': {'lat': 40.88593, 'lon': -74.04347}}, {'zip': '58122', 'city': 'Fargo', 'state': 'North Dakota', 'status': 'COMPLETED', 'country': 'United States', 'facility': 'Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 2708)', 'geoPoint': {'lat': 46.87719, 'lon': -96.7898}}, {'zip': '75390', 'city': 'Dallas', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '888-577-8839'}], 'facility': 'UT Southwestern-Harold C. Simmons Cancer Center ( Site 2730)', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '99208', 'city': 'Spokane', 'state': 'Washington', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '509-462-2273'}], 'facility': 'Medical Oncology Associates (Summit Cancer Centers) ( Site 2710)', 'geoPoint': {'lat': 47.65966, 'lon': -117.42908}}, {'zip': 'C1118AAT', 'city': 'Ciudad Autonoma de Buenos Aires', 'state': 'Buenos Aires', 'status': 'RECRUITING', 'country': 'Argentina', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+541148277000'}], 'facility': 'Hospital Aleman ( Site 0102)'}, {'zip': 'C1431FWO', 'city': 'Buenos Aires', 'state': 'Buenos Aires F.D.', 'status': 'RECRUITING', 'country': 'Argentina', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+541152990247'}], 'facility': 'Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 0103)', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'zip': 'S2000DEJ', 'city': 'Rosario', 'state': 'Santa Fe Province', 'status': 'RECRUITING', 'country': 'Argentina', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+54 0341 238 4171'}], 'facility': 'Fundacion Estudios Clinicos ( Site 0112)', 'geoPoint': {'lat': -32.94682, 'lon': -60.63932}}, {'zip': 'C1114AAN', 'city': 'Caba', 'status': 'RECRUITING', 'country': 'Argentina', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '5411 48771046'}], 'facility': 'FUNDALEU ( Site 0104)'}, {'zip': 'X5016KEH', 'city': 'Córdoba', 'status': 'RECRUITING', 'country': 'Argentina', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+541569634187'}], 'facility': 'Hospital Privado Universitario de Córdoba ( Site 0107)', 'geoPoint': {'lat': -31.40648, 'lon': -64.18853}}, {'zip': 'M5500AYB', 'city': 'Mendoza', 'status': 'COMPLETED', 'country': 'Argentina', 'facility': 'Fundacion Centro Oncologico de Integración Regional-Medical Oncology ( Site 0110)', 'geoPoint': {'lat': -32.88946, 'lon': -68.84582}}, {'zip': '2747', 'city': 'Sydney', 'state': 'New South Wales', 'status': 'COMPLETED', 'country': 'Australia', 'facility': 'Nepean Hospital-Nepean Cancer Care Centre ( Site 0204)', 'geoPoint': {'lat': -33.86785, 'lon': 151.20732}}, {'zip': '3128', 'city': 'Box Hill', 'state': 'Victoria', 'status': 'RECRUITING', 'country': 'Australia', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+611300342255'}], 'facility': 'Box Hill Hospital ( Site 0203)', 'geoPoint': {'lat': -37.81887, 'lon': 145.12545}}, {'zip': '6009', 'city': 'Nedlands', 'state': 'Western Australia', 'status': 'RECRUITING', 'country': 'Australia', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+61864573333'}], 'facility': 'Sir Charles Gairdner Hospital ( Site 0200)', 'geoPoint': {'lat': -31.98184, 'lon': 115.8073}}, {'zip': '05403-000', 'city': 'São Paulo', 'state': 'São Paulo', 'status': 'RECRUITING', 'country': 'Brazil', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '551145737543'}], 'facility': 'Hospital das Clinicas FMUSP-Pesquisa Clínica Hematologia ( Site 0303)', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'zip': '20231-050', 'city': 'Rio de Janeiro', 'status': 'RECRUITING', 'country': 'Brazil', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+552132076564'}], 'facility': 'Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0300)', 'geoPoint': {'lat': -22.90642, 'lon': -43.18223}}, {'zip': '01321-001', 'city': 'São Paulo', 'status': 'COMPLETED', 'country': 'Brazil', 'facility': 'BP - A Beneficencia Portuguesa de São Paulo ( Site 0302)', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'zip': '01321-001', 'city': 'São Paulo', 'status': 'RECRUITING', 'country': 'Brazil', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+551130161340'}], 'facility': 'Hospital Paulistano - Amil Clinical Research ( Site 0311)', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'zip': 'T2N 5G2', 'city': 'Calgary', 'state': 'Alberta', 'status': 'RECRUITING', 'country': 'Canada', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '4035213723'}], 'facility': 'Arthur J.E. Child Comprehensive Cancer Centre ( Site 0401)', 'geoPoint': {'lat': 51.05011, 'lon': -114.08529}}, {'zip': 'K1H 8L6', 'city': 'Ottawa', 'state': 'Ontario', 'status': 'RECRUITING', 'country': 'Canada', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '613 737-7700'}], 'facility': 'The Ottawa Hospital ( Site 0404)', 'geoPoint': {'lat': 45.41117, 'lon': -75.69812}}, {'zip': 'M5G 2M9', 'city': 'Toronto', 'state': 'Ontario', 'status': 'RECRUITING', 'country': 'Canada', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '416-946-2827'}], 'facility': 'Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0406)', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}, {'zip': 'H1T 2M4', 'city': 'Montreal', 'state': 'Quebec', 'status': 'RECRUITING', 'country': 'Canada', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '5142523400'}], 'facility': 'CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0403)', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'zip': 'H3T 1E2', 'city': 'Montreal', 'state': 'Quebec', 'status': 'RECRUITING', 'country': 'Canada', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '5143408222 x 24572'}], 'facility': 'Jewish General Hospital ( Site 0400)', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'zip': '230071', 'city': 'Hefei', 'state': 'Anhui', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '13866173932'}], 'facility': 'Anhui Provincial Hospital ( Site 2808)', 'geoPoint': {'lat': 31.86389, 'lon': 117.28083}}, {'zip': '100191', 'city': 'Beijing', 'state': 'Beijing Municipality', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '010-82266699'}], 'facility': 'Peking University Third Hospital-Hematology ( Site 2827)', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'zip': '400072', 'city': 'Chongqing', 'state': 'Chongqing Municipality', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '023-62887282'}], 'facility': 'The Second Affiliated Hospital of Chongqing Medical University ( Site 2825)', 'geoPoint': {'lat': 29.56026, 'lon': 106.55771}}, {'zip': '510060', 'city': 'Guangzhou', 'state': 'Guangdong', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '(+86)13719189172'}], 'facility': 'Sun Yat-sen University Cancer Center-Internal Medicine ( Site 2824)', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'zip': '545006', 'city': 'Liuchow', 'state': 'Guangxi', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '13877299966'}], 'facility': 'Guangxi Medical University - Liuzhou Renmin Hospital ( Site 2817)', 'geoPoint': {'lat': 24.32405, 'lon': 109.40698}}, {'zip': '530201', 'city': 'Nanning', 'state': 'Guangxi', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '07715778582'}], 'facility': 'Guangxi Medical University Affiliated Tumor Hospital ( Site 2814)', 'geoPoint': {'lat': 22.81667, 'lon': 108.31667}}, {'zip': '450008', 'city': 'Zhengzhou', 'state': 'Henan', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '0371-65588007'}], 'facility': 'Henan Cancer Hospital-hematology department ( Site 2802)', 'geoPoint': {'lat': 34.75778, 'lon': 113.64861}}, {'zip': '430022', 'city': 'Wuhan', 'state': 'Hubei', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+8618627091655'}], 'facility': 'Wuhan Union Hospital ( Site 2816)', 'geoPoint': {'lat': 30.58333, 'lon': 114.26667}}, {'zip': '410011', 'city': 'Changsha', 'state': 'Hunan', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+8613975806137'}], 'facility': 'The Second Xiangya Hospital of Central South University ( Site 2820)', 'geoPoint': {'lat': 28.19874, 'lon': 112.97087}}, {'zip': '410013', 'city': 'Changsha', 'state': 'Hunan', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '0731-88651669'}], 'facility': 'Hunan Cancer Hospital ( Site 2822)', 'geoPoint': {'lat': 28.19874, 'lon': 112.97087}}, {'zip': '210029', 'city': 'Nanjing', 'state': 'Jiangsu', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '025-86211033'}], 'facility': 'Jiangsu Province Hospital ( Site 2823)', 'geoPoint': {'lat': 32.06167, 'lon': 118.77778}}, {'zip': '221000', 'city': 'Xuzhou', 'state': 'Jiangsu', 'status': 'COMPLETED', 'country': 'China', 'facility': 'The Affiliated Hospital of Xuzhou Medical College ( Site 2818)', 'geoPoint': {'lat': 34.20442, 'lon': 117.28386}}, {'zip': '330006', 'city': 'Nanchang', 'state': 'Jiangxi', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '13970038386'}], 'facility': 'The First Affiliated Hospital of Nanchang University ( Site 2815)', 'geoPoint': {'lat': 28.68396, 'lon': 115.85306}}, {'zip': '130021', 'city': 'Changchun', 'state': 'Jilin', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '0431-88786014'}], 'facility': 'The First Hospital of Jilin University-Hematology ( Site 2803)', 'geoPoint': {'lat': 43.88, 'lon': 125.32278}}, {'zip': '200032', 'city': 'Shanghai', 'state': 'Shanghai Municipality', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+8602164175590'}], 'facility': 'Fudan University Shanghai Cancer Center ( Site 2801)', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'zip': '200040', 'city': 'Shanghai', 'state': 'Shanghai Municipality', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '021-52889999'}], 'facility': 'Huashan Hospital, Fudan University ( Site 2821)', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'zip': '610041', 'city': 'Chengdu', 'state': 'Sichuan', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+86028-85422114'}], 'facility': 'West China Hospital Sichuan University ( Site 2810)', 'geoPoint': {'lat': 30.66667, 'lon': 104.06667}}, {'zip': '301617', 'city': 'Tianjin', 'state': 'Tianjin Municipality', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+8615900265415'}], 'facility': 'Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Unio ( Site 2800)', 'geoPoint': {'lat': 39.14222, 'lon': 117.17667}}, {'zip': '310002', 'city': 'Hangzhou', 'state': 'Zhejiang', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '057187236114'}], 'facility': 'The First Affiliated Hospital, Zhejiang University ( Site 2826)', 'geoPoint': {'lat': 30.29365, 'lon': 120.16142}}, {'zip': '625 00', 'city': 'Brno', 'state': 'Brno-mesto', 'status': 'RECRUITING', 'country': 'Czechia', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+420532233642'}], 'facility': 'Fakultní nemocnice Brno Bohunice-Interni hematologicka a onkologicka klinika ( Site 0600)', 'geoPoint': {'lat': 49.19522, 'lon': 16.60796}}, {'zip': '500 05', 'city': 'Hradec Králové', 'status': 'RECRUITING', 'country': 'Czechia', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+420495832159'}], 'facility': 'Fakultni nemocnice Hradec Kralove ( Site 0601)', 'geoPoint': {'lat': 50.20923, 'lon': 15.83277}}, {'zip': '8200', 'city': 'Aarhus N', 'state': 'Central Jutland', 'status': 'COMPLETED', 'country': 'Denmark', 'facility': 'Aarhus University Hospital ( Site 0702)', 'geoPoint': {'lat': 56.20367, 'lon': 10.17317}}, {'zip': '9000', 'city': 'Aalborg', 'state': 'North Denmark', 'status': 'RECRUITING', 'country': 'Denmark', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+45 97660000'}], 'facility': 'Aalborg Universitetshospital ( Site 0703)', 'geoPoint': {'lat': 57.048, 'lon': 9.9187}}, {'zip': '4000', 'city': 'Roskilde', 'state': 'Region Sjælland', 'status': 'RECRUITING', 'country': 'Denmark', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+45 46323200'}], 'facility': 'Sjaellands Universitetshospital Roskilde ( Site 0701)', 'geoPoint': {'lat': 55.64152, 'lon': 12.08035}}, {'zip': '5000', 'city': 'Odense C', 'state': 'Region Syddanmark', 'status': 'COMPLETED', 'country': 'Denmark', 'facility': 'Odense University Hospital ( Site 0705)', 'geoPoint': {'lat': 55.40841, 'lon': 10.39538}}, {'zip': '06202', 'city': 'Nice', 'state': 'Alpes-Maritimes', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+33 4 92 03 57 85'}], 'facility': "Centre Hospitalier Universitaire de Nice - Hôpital l'Archet ( Site 0810)", 'geoPoint': {'lat': 43.70313, 'lon': 7.26608}}, {'zip': '69495', 'city': 'Pierre-Bénite', 'state': 'Auvergne-Rhône-Alpes', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+33478864348'}], 'facility': 'Centre Hospitalier Lyon-Sud ( Site 0804)', 'geoPoint': {'lat': 45.70359, 'lon': 4.82424}}, {'zip': '13009', 'city': 'Marseille', 'state': 'Bouches-du-Rhone', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+33491223537'}], 'facility': 'Institut Paoli-Calmettes ( Site 0803)', 'geoPoint': {'lat': 43.29695, 'lon': 5.38107}}, {'zip': '78150', 'city': 'Le Chesnay', 'state': 'Yvelines', 'status': 'COMPLETED', 'country': 'France', 'facility': 'Centre Hospitalier de Versailles ( Site 0809)', 'geoPoint': {'lat': 48.8222, 'lon': 2.12213}}, {'zip': '75010', 'city': 'Paris', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+33142499236'}], 'facility': 'Hopital Saint Louis ( Site 0805)', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '89081', 'city': 'Ulm', 'state': 'Baden-Wurttemberg', 'status': 'RECRUITING', 'country': 'Germany', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+ 49 731 500 45901'}], 'facility': 'Universitaetsklinikum Ulm. ( Site 0906)', 'geoPoint': {'lat': 48.39841, 'lon': 9.99155}}, {'zip': '50937', 'city': 'Cologne', 'state': 'North Rhine-Westphalia', 'status': 'RECRUITING', 'country': 'Germany', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+4922147897046'}], 'facility': 'Universitaetsklinikum Koeln ( Site 0901)', 'geoPoint': {'lat': 50.93333, 'lon': 6.95}}, {'zip': '57072', 'city': 'Siegen', 'state': 'North Rhine-Westphalia', 'status': 'COMPLETED', 'country': 'Germany', 'facility': 'St. Marien-Krankenhaus Siegen ( Site 0914)', 'geoPoint': {'lat': 50.87481, 'lon': 8.02431}}, {'zip': '01307', 'city': 'Dresden', 'state': 'Saxony', 'status': 'RECRUITING', 'country': 'Germany', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '0049 351 458 5692'}], 'facility': 'Universitaetsklinikum Carl Gustav Carus ( Site 0902)', 'geoPoint': {'lat': 51.05089, 'lon': 13.73832}}, {'zip': '7624', 'city': 'Pécs', 'state': 'Baranya', 'status': 'RECRUITING', 'country': 'Hungary', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+3672536000'}], 'facility': 'Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar ( Site 1202)', 'geoPoint': {'lat': 46.07617, 'lon': 18.22814}}, {'zip': '4032', 'city': 'Debrecen', 'state': 'Hajdú-Bihar', 'status': 'RECRUITING', 'country': 'Hungary', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+3652255196'}], 'facility': 'Debreceni Egyetem Klinikai Kozpont ( Site 1201)', 'geoPoint': {'lat': 47.53167, 'lon': 21.62444}}, {'zip': '4400', 'city': 'Nyíregyháza', 'state': 'Szabolcs-Szatmár-Bereg', 'status': 'RECRUITING', 'country': 'Hungary', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+3642599700'}], 'facility': 'Szabolcs Szatmár Bereg Vármegyei Oktatókórház ( Site 1206)', 'geoPoint': {'lat': 47.95539, 'lon': 21.71671}}, {'zip': '1122', 'city': 'Budapest', 'status': 'RECRUITING', 'country': 'Hungary', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+3612248600'}], 'facility': 'Orszagos Onkologiai Intezet ( Site 1200)', 'geoPoint': {'lat': 47.49835, 'lon': 19.04045}}, {'zip': 'Dublin 9', 'city': 'Dublin', 'status': 'RECRUITING', 'country': 'Ireland', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+35318092010'}], 'facility': 'Beaumont Hospital ( Site 2900)', 'geoPoint': {'lat': 53.33306, 'lon': -6.24889}}, {'zip': 'V94 F858', 'city': 'Limerick', 'status': 'RECRUITING', 'country': 'Ireland', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+35361588320'}], 'facility': 'University Hospital Limerick ( Site 2903)', 'geoPoint': {'lat': 52.66472, 'lon': -8.62306}}, {'zip': '1834111', 'city': 'Afula', 'status': 'RECRUITING', 'country': 'Israel', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '972-46494052'}], 'facility': 'Ha Emek Medical Center ( Site 1305)', 'geoPoint': {'lat': 32.60907, 'lon': 35.2892}}, {'zip': '8457108', 'city': 'Beersheba', 'status': 'RECRUITING', 'country': 'Israel', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+97286403827'}], 'facility': 'Soroka Medical Center ( Site 1307)', 'geoPoint': {'lat': 31.25181, 'lon': 34.7913}}, {'zip': '3109601', 'city': 'Haifa', 'status': 'RECRUITING', 'country': 'Israel', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+97247772547'}], 'facility': 'Rambam Medical Center ( Site 1301)', 'geoPoint': {'lat': 32.81303, 'lon': 34.99928}}, {'zip': '9112001', 'city': 'Jerusalem', 'status': 'RECRUITING', 'country': 'Israel', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+97226778180'}], 'facility': 'Hadassah Ein Karem Jerusalem ( Site 1300)', 'geoPoint': {'lat': 31.76904, 'lon': 35.21633}}, {'zip': '5262001', 'city': 'Ramat Gan', 'status': 'RECRUITING', 'country': 'Israel', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+97235308401'}], 'facility': 'Chaim Sheba Medical Center ( Site 1302)', 'geoPoint': {'lat': 32.08227, 'lon': 34.81065}}, {'zip': '76100', 'city': 'Rehovot', 'status': 'RECRUITING', 'country': 'Israel', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+97289441726'}], 'facility': 'Kaplan Medical Center ( Site 1304)', 'geoPoint': {'lat': 31.89421, 'lon': 34.81199}}, {'zip': '6423906', 'city': 'Tel Aviv', 'status': 'RECRUITING', 'country': 'Israel', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+97236973782'}], 'facility': 'Sourasky Medical Center ( Site 1303)', 'geoPoint': {'lat': 32.08088, 'lon': 34.78057}}, {'zip': '70124', 'city': 'Bari', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+390805555905'}], 'facility': 'Istituto Tumori Giovanni Paolo II ( Site 1409)', 'geoPoint': {'lat': 41.12066, 'lon': 16.86982}}, {'zip': '40138', 'city': 'Bologna', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+390516363680'}], 'facility': 'A.O. Universitaria Policlinico S. Orsola-Malpighi ( Site 1400)', 'geoPoint': {'lat': 44.49381, 'lon': 11.33875}}, {'zip': '25123', 'city': 'Brescia', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+39 0303996416'}], 'facility': 'ASST Spedali Civili di Brescia ( Site 1408)', 'geoPoint': {'lat': 45.53558, 'lon': 10.21472}}, {'zip': '20132', 'city': 'Milan', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '00390226434797'}], 'facility': 'IRCCS Ospedale San Raffaele ( Site 1402)', 'geoPoint': {'lat': 42.78235, 'lon': 12.59836}}, {'zip': '80131', 'city': 'Napoli', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+39 0815903 382'}], 'facility': 'Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1403)', 'geoPoint': {'lat': 40.87618, 'lon': 14.5195}}, {'zip': '27100', 'city': 'Pavia', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+39 0382503084'}], 'facility': 'Fondazione IRCCS Policlinico San Matteo ( Site 1407)', 'geoPoint': {'lat': 45.19205, 'lon': 9.15917}}, {'zip': '42123', 'city': 'Reggio Emilia', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+39 0522295654'}], 'facility': 'IRCCS - Arcispedale Santa Maria Nuova ( Site 1405)', 'geoPoint': {'lat': 44.69825, 'lon': 10.63125}}, {'zip': '00161', 'city': 'Roma', 'status': 'COMPLETED', 'country': 'Italy', 'facility': 'Policlinico Umberto I ( Site 1404)', 'geoPoint': {'lat': 44.99364, 'lon': 11.10642}}, {'zip': '30-727', 'city': 'Krakow', 'state': 'Lesser Poland Voivodeship', 'status': 'RECRUITING', 'country': 'Poland', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '48 12 2954135'}], 'facility': 'Pratia MCM Krakow ( Site 1601)', 'geoPoint': {'lat': 50.06143, 'lon': 19.93658}}, {'zip': '50-367', 'city': 'Wroclaw', 'state': 'Lower Silesian Voivodeship', 'status': 'RECRUITING', 'country': 'Poland', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+48717842576'}], 'facility': 'Uniwersytecki Szpital Kliniczny-Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku ( Site 1606)', 'geoPoint': {'lat': 51.10286, 'lon': 17.03006}}, {'zip': '02-781', 'city': 'Warsaw', 'state': 'Masovian Voivodeship', 'status': 'RECRUITING', 'country': 'Poland', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+48225462223'}], 'facility': 'Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Kilinka Onkologii I Hematologii ( Site 1608)', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '45-061', 'city': 'Opole', 'state': 'Opole Voivodeship', 'status': 'COMPLETED', 'country': 'Poland', 'facility': 'Szpital Wojewódzki w Opolu-Hematology Department ( Site 1607)', 'geoPoint': {'lat': 50.67119, 'lon': 17.92604}}, {'zip': '81-519', 'city': 'Gdynia', 'state': 'Pomeranian Voivodeship', 'status': 'COMPLETED', 'country': 'Poland', 'facility': 'Szpitale Pomorskie Sp. z o.o. ( Site 1600)', 'geoPoint': {'lat': 54.51889, 'lon': 18.53188}}, {'zip': '030171', 'city': 'Bucharest', 'state': 'București', 'status': 'RECRUITING', 'country': 'Romania', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '0040213874100'}], 'facility': 'Spitalul Clinic Colțea ( Site 1805)', 'geoPoint': {'lat': 44.43225, 'lon': 26.10626}}, {'zip': '905900', 'city': 'Ovidiu', 'state': 'Constanța County', 'status': 'COMPLETED', 'country': 'Romania', 'facility': 'Ovidius Clinical Hospital ( Site 1804)', 'geoPoint': {'lat': 44.258, 'lon': 28.56083}}, {'zip': '500052', 'city': 'Brasov', 'status': 'RECRUITING', 'country': 'Romania', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '0729075567'}], 'facility': 'Centrul de Diagnostic si Tratament Oncologic Brasov ( Site 1802)', 'geoPoint': {'lat': 45.64861, 'lon': 25.60613}}, {'zip': '700483', 'city': 'Iași', 'status': 'RECRUITING', 'country': 'Romania', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '40374278811'}], 'facility': 'Institutul Regional de Oncologie Iasi ( Site 1801)', 'geoPoint': {'lat': 47.16667, 'lon': 27.6}}, {'zip': '03722', 'city': 'Seoul', 'status': 'RECRUITING', 'country': 'South Korea', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+82222281972'}], 'facility': 'Severance Hospital Yonsei University Health System ( Site 2201)', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '06351', 'city': 'Seoul', 'status': 'RECRUITING', 'country': 'South Korea', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+82234106548'}], 'facility': 'Samsung Medical Center ( Site 2200)', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '08908', 'city': "L'Hospitalet de Llobregat", 'state': 'Barcelona', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+34932607750'}], 'facility': 'Instituto Catalan de Oncologia ICO - Hospital Duran i Reynals ( Site 2000)', 'geoPoint': {'lat': 41.35967, 'lon': 2.10028}}, {'zip': '37007', 'city': 'Salamanca', 'state': 'Castille and León', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '34923 29 11 00x55974'}], 'facility': 'Hospital Universitario de Salamanca ( Site 2002)', 'geoPoint': {'lat': 40.96882, 'lon': -5.66388}}, {'zip': '15006', 'city': 'A Coruña', 'state': 'La Coruna', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '34981178000'}], 'facility': 'CHUAC-Complejo Hospitalario Universitario A Coruña ( Site 2005)', 'geoPoint': {'lat': 43.37135, 'lon': -8.396}}, {'zip': '03010', 'city': 'Alicante', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '965 93 30 00'}], 'facility': 'Hospital General Universitario de Alicante ( Site 2007)', 'geoPoint': {'lat': 38.34517, 'lon': -0.48149}}, {'zip': '08035', 'city': 'Barcelona', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+34934893806'}], 'facility': "Hospital Universitari Vall d'Hebron ( Site 2001)", 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '28041', 'city': 'Madrid', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+34917792809'}], 'facility': 'Hospital Universitario 12 de Octubre ( Site 2003)', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28222', 'city': 'Madrid', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+34911916000'}], 'facility': 'Hospital Puerta de Hierro ( Site 2009)', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '3010', 'city': 'Bern', 'state': 'Canton of Bern', 'status': 'RECRUITING', 'country': 'Switzerland', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+41316329023'}], 'facility': 'Inselspital Bern ( Site 2303)', 'geoPoint': {'lat': 46.94809, 'lon': 7.44744}}, {'zip': '6500', 'city': 'Bellinzona', 'state': 'Canton Ticino', 'status': 'RECRUITING', 'country': 'Switzerland', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+41918118540'}], 'facility': 'Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 2302)', 'geoPoint': {'lat': 46.19278, 'lon': 9.01703}}, {'zip': '34214', 'city': 'Stanbul', 'state': 'Istanbul', 'status': 'ACTIVE_NOT_RECRUITING', 'country': 'Turkey (Türkiye)', 'facility': 'Mega Medipol-Hematology ( Site 2406)'}, {'zip': '06590', 'city': 'Ankara', 'status': 'RECRUITING', 'country': 'Turkey (Türkiye)', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+903125957099'}], 'facility': 'Ankara Universitesi Tip Fakultesi Cebeci Hastanesi ( Site 2400)', 'geoPoint': {'lat': 39.91987, 'lon': 32.85427}}, {'zip': '34365', 'city': 'Istanbul', 'status': 'COMPLETED', 'country': 'Turkey (Türkiye)', 'facility': 'VKV Amerikan Hastanesi ( Site 2403)', 'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}, {'zip': '34381', 'city': 'Istanbul', 'status': 'RECRUITING', 'country': 'Turkey (Türkiye)', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+90 542 502 50 75'}], 'facility': 'Sisli Florence Nightingale Hastanesi ( Site 2407)', 'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}, {'zip': '35340', 'city': 'Izmir', 'status': 'ACTIVE_NOT_RECRUITING', 'country': 'Turkey (Türkiye)', 'facility': 'Dokuz Eylül Üniversitesi-Hematology ( Site 2402)', 'geoPoint': {'lat': 38.41273, 'lon': 27.13838}}, {'zip': '18009', 'city': 'Cherkassy', 'state': 'Cherkasy Oblast', 'status': 'RECRUITING', 'country': 'Ukraine', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+380634253209'}], 'facility': 'MNPE ClinCenter of Oncology,Hematology,Transplantology and Palliative Care of CherkasyRegCouncil ( Site 2509)', 'geoPoint': {'lat': 49.44452, 'lon': 32.05738}}, {'zip': '76008', 'city': 'Ivano-Frankivsk', 'state': 'Ivano-Frankivsk Oblast', 'status': 'COMPLETED', 'country': 'Ukraine', 'facility': 'Communal non-profit enterprise "Regional clinical hospital o-Hematology Department ( Site 2510)', 'geoPoint': {'lat': 48.92312, 'lon': 24.71248}}, {'zip': '79044', 'city': 'Lviv', 'state': 'Lviv Oblast', 'status': 'RECRUITING', 'country': 'Ukraine', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+380322352276'}], 'facility': 'Instit. of Blood Transfusion Medicine of the National Academy ( Site 2506)', 'geoPoint': {'lat': 49.83826, 'lon': 24.02324}}, {'zip': '03022', 'city': 'Kyiv', 'status': 'RECRUITING', 'country': 'Ukraine', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+380672091427'}], 'facility': 'National Cancer Institute ( Site 2507)', 'geoPoint': {'lat': 50.45466, 'lon': 30.5238}}, {'zip': '04112', 'city': 'Kyiv', 'status': 'RECRUITING', 'country': 'Ukraine', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+380509105840'}], 'facility': 'Kyiv City Clinical Hospital 9 ( Site 2502)', 'geoPoint': {'lat': 50.45466, 'lon': 30.5238}}, {'zip': 'BS2 8ED', 'city': 'Bristol', 'state': 'Bristol, City of', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '01173426733'}], 'facility': 'Bristol Haematology and Oncology Centre ( Site 2610)', 'geoPoint': {'lat': 51.45523, 'lon': -2.59665}}, {'zip': 'NG5 1PF', 'city': 'Nottingham', 'state': 'England', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+441159691169'}], 'facility': 'Nottingham University Hospitals NHS Trust. City Hospital Campus ( Site 2601)', 'geoPoint': {'lat': 52.9536, 'lon': -1.15047}}, {'zip': 'SL4 3HD', 'city': 'Windsor', 'state': 'England', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+447989474250'}], 'facility': 'GenesisCare - Windsor ( Site 2608)', 'geoPoint': {'lat': 51.48333, 'lon': -0.6}}, {'zip': 'W1G 6AD', 'city': 'London', 'state': 'London, City of', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '02032195234'}], 'facility': 'Sarah Cannon Research Institute UK ( Site 2612)', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'OX4 6LB', 'city': 'Oxford', 'state': 'Oxfordshire', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+447989474250'}], 'facility': 'GenesisCare - Oxford ( Site 2607)', 'geoPoint': {'lat': 51.75222, 'lon': -1.25596}}, {'zip': 'CB8 7XN', 'city': 'Newmarket', 'state': 'Suffolk', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '01223 655145'}], 'facility': 'GenesisCare - Cambridge ( Site 2611)', 'geoPoint': {'lat': 52.24467, 'lon': 0.40418}}, {'zip': 'SM2 5PT', 'city': 'Sutton', 'state': 'Surrey', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '020 8642 6011'}], 'facility': 'The Royal Marsden NHS Foundation Trust. ( Site 2606)', 'geoPoint': {'lat': 51.35, 'lon': -0.2}}, {'zip': 'M20 4BX', 'city': 'Manchester', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '01619561217'}], 'facility': 'The Christie NHS Foundation Trust ( Site 2602)', 'geoPoint': {'lat': 53.48095, 'lon': -2.23743}}], 'centralContacts': [{'name': 'Toll Free Number', 'role': 'CONTACT', 'email': 'Trialsites@msd.com', 'phone': '1-888-577-8839'}], 'overallOfficials': [{'name': 'Medical Director', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Merck Sharp & Dohme LLC'}]}, 'ipdSharingStatementModule': {'url': 'https://externaldatasharing-msd.com/', 'ipdSharing': 'YES', 'description': 'https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Merck Sharp & Dohme LLC', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}